We secured regulatory approval following a lengthy review

Davis Polk successfully secured FTC clearance of Novo Nordisk’s $11 billion acquisition of three fill-finish sites from Novo Holdings A/S in connection with the acquisition of Catalent, Inc. by Novo Holdings. The three manufacturing sites are specialized in sterile filling of drugs and located in Anagni, Italy; Brussels, Belgium; and Bloomington, Indiana. The three sites employ more than 3,000 people and all have ongoing collaborations with Novo Nordisk. The FTC issued a second request seeking additional information about the transaction in May 2024. Following a lengthy review, and despite stiff contention from industry and public interest groups, the FTC cleared the transaction, which closed on December 18, 2024.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Its purpose is to drive change to defeat serious chronic diseases, built upon its heritage in diabetes. Novo Nordisk does so by pioneering scientific breakthroughs, expanding access to its medicines and working to prevent and ultimately cure disease.

Novo Holdings is a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation. Novo Holdings is the controlling shareholder of Novo Nordisk and manages an investment portfolio with a long-term return perspective.

Catalent is a global contract development and manufacturing organization headquartered in Somerset, New Jersey. The company has over 50 global sites and employs more than 18,000 people, including 3,000 scientists and technicians.

The Davis Polk antitrust and competition team included partner Arthur J. Burke and counsel Gregory S. Morrison, Suzanne Munck af Rosenschold and Gil Ohana. Members of the Davis Polk team are based in the New York, Washington DC and Northern California offices.

 

Copy link to share post